Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-25T16:13:07.609Z Has data issue: false hasContentIssue false
  • English
  • Français

Possible antidepressant/mania-inducing effects of methionine: a reappraisal of the effects of methionine in chronic psychosis using modern diagnostic criteria

Published online by Cambridge University Press:  28 April 2020

J.F. Lipinski Jr  and
R.C. Alexander
J.F. Lipinski Jr
Affiliation:
The Laboratories for Psychiatric Research, Mailman Research Center, 115 Mill Street, McLean Hospital, Belmont, MA02178 The Department of Psychiatry, Harvard Medical School, Boston, MA02115, USA
R.C. Alexander*
Affiliation:
The Laboratories for Psychiatric Research, Mailman Research Center, 115 Mill Street, McLean Hospital, Belmont, MA02178 The Department of Psychiatry, Harvard Medical School, Boston, MA02115, USA
*
*Present address: Neuropsychiatry Branch, National Institutes of Mental Health, St. Elizabeth's Hospital, Washington, DC 20032, USA.
Get access

Summary

The authors have reviewed 13 published studies on methionine administration, usually in combination with a monoamine oxidase inhibitor (MAOI), to chronically psychotic patients, using modern (DSM-III) diagnostic criteria. Four of these studies contained sufficient descriptive data to allow reappraisal of the effects. The results of the review suggest that a proportion of the patients experienced the induction of a manic episode/antidepressant effects rather than the reported worsening of schizophrenia while treated with a methionine-MAOI combination. It is suggested that these observations are consistent with recent findings that S-adenosyl-L-methionine (SAMe) has antidepressant and mania-inducing effects.

Résumé

Résumé

Les auteurs examinent 13 études publiées sur l’administration de la méthionine, en général en association avec un inhibiteur de monoamine oxidase (IMAO) pour des patients psychotiques chroniques diagnostiqués avec la méthode du DSMIII. Les résultats suggèrent que certains patients font un épisode maniaque (effet antidépresseur) au lieu d’une aggravation de symptômes schizophréniques à la suite du traitement à la méthionine et IMAO. Ces observations sont en accord avec des études récentes montrant que S-adenosyl méthionine (SAMe) a un effet antidépresseur et peut déclencher un accès maniaque.

Keywords

methionineschizophreniamonoamine oxidase inhibitorsmaniapsychosisméthionineschizophrénieinhibiteurs de monoamine oxydasemaniepsychose
Type
Original article
Information
Psychiatry and Psychobiology , Volume 4 , Issue 3 , 1989 , pp. 175 - 181
Copyright
Copyright © European Psychiatric Association 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agnoli, A.Andreoli, V.Casacchia, M. & Cerbo, R. (1976) Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J. Psychiat. Res. 13, 43–54CrossRefGoogle ScholarPubMed
Agnoli, A.Andreoli, V.M.Casacchia, M.Maffei, F. & Fazio, D. (1978) In: Transmethylations and the Central Nervous System (V.M., AndreoliA., Agnoli and C., Fazio, eds.), Springer Verlag, New York, pp. 170–182Google Scholar
Alexander, F.Curtis, G.C.Sprince, H. & Crosley, A.P. (1963) L-methionine and L-tryptophan feedings in non-psychotic and schizophrenic patients with and without tranylcypromine. J. Nerv. Ment. Dis. 137, 447–450CrossRefGoogle ScholarPubMed
Ananth, J.V.Ban, T.A.Lehmann, H.E. & Bennett, J. (1970) Nicotinic aid in the prevention of methionine-induced exacerbation of psychopathology in schizophrenia. Can. Psychiatr. Am. J. 15, 15–20Google Scholar
Antun, F.T.Burnett, G.B.Cooper, A.S.Daly, R.J.Smythies, J.R. & Zealley, A.K. (1971) The effects of L-methionine (without MAOI) in schizophrenia. J. Psychiatr. Res. 8, 63–71CrossRefGoogle Scholar
Baldessarini, R.J. (1986) Alterations in tissue levels of Sadenosyl- L-methionine. Biochem. Pharmacol. 15, 741–748CrossRefGoogle Scholar
Barberi, A. & Pusateri, C. (1978) Sugli effeti clinici della S-adenosil-L-metionina (SAMe) nelle sindromi depressive. Minerva Psichiatr. 19, 235–243Google Scholar
Bell, K.M.Plon, L.Bunney, W.E. & Potkin, S.G. (1988) S-adenosylmethionine treatment of depression : a controlled clinical trial. Am. J. Psychiatry 145, 1110–1114Google ScholarPubMed
Berlet, H.H.Matsumoto, K.Pscheidt, G.R.Spaide, J.Bull, C. & Himwich, H.E. (1965) Biochemical correlates of behavior in schizophrenic patients. Arch. Gen. Psychiatry 13, 521–531CrossRefGoogle ScholarPubMed
Brune, G.G. & Himwich, H.E. (1962) Effects of methionine loading on the behavior of schizophrenic patients. J. Nerv. Ment. Dis. 134, 447–450CrossRefGoogle ScholarPubMed
Calandra, C.Roxas, M. & Rapisarda, V. (1979) Azione antidepressiva della SAMe a paragine della clorimipramina. Minerva Psichiatr. 20, 147–152Google Scholar
Carney, M.W.P.Martin, R.Battiglieri, J. et al. (1983) The switch mechanism in affective illness and SAMe. Lancet 1, 820–821CrossRefGoogle Scholar
Caruso, l.Fumagalli, M.Boccassini, L.Puttini, P.S.Ciniselli, G. & Cavallari, G. (1984) Antidepressant activity of S-adenosyl-methionine. Lancet i, 904CrossRefGoogle Scholar
Cohen, S.M.Nichols, A.Wyatt, R. & Pollin, W. (1974) The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol. Psychiatry 8, 209–225Google ScholarPubMed
Del Vecchio, M.loro, G.Cocorallo, M.Vacca, L. & Amati, A. (1978) Has SAMe (Ado Met) an antidepressant effect? A preliminary trial versus chlorimipramine. Rlv. Speriment. Freniatr. 102, 344–358Google Scholar
Diagnostic and Statistical Manual of Mental Disorders. Third Edition. Revised. American Psychiatric Association. Washington, DC, 1987, pp. 214-218Google Scholar
Fazio, C.Andreoli, V.Agnoli, A.Casacchia, M. & Carbo, R. (1973) Effetti terapeutici e meccanismo d’azione della S-adenosyl-L-metionina (SAMe) nelle sindromi depressive. Minerva Med. (Torino) 64, 1515–1529Google Scholar
Fazio, C.Andreoli, V.Agnoli, A.Casacchia, M.Carbo, R. & Pinzello, A. (1974) Therapy of schizophrenia and depressive disorders with S-adenosyl-L-methionine. Inter. Res. Comm. System. Clin. Pharmacol. Ther. 2, 1015Google Scholar
Goodwin, F.K. (1983) The impact of tricyclic antidepressant and lithium on the course of recurrent affective disorders. McLean J. 8, 1–16Google Scholar
Haydu, G.G.Dhrymiotis, A.Kronyi, C. & Goldschmidt, L. (1965) Effects of methionine and hydroxychloroquine in schizophrenia. Am. J. Psychiatry 122, 560–564CrossRefGoogle Scholar
Jus, A.Rosengarten, H.Wardaszko-Lyskowska Szemis, I.Wiosinska, J.Krzyzowski, K.Stenka, K. & Kowalska, K. (1970) Correlations between disturbances of tryptophan metabolism provoked by methionine and nialamide administration and changes of the psychic State in chronic schizophrenic patients. Psychiatr. Pol. Rok. 4, 365–371Google Scholar
Kakimoto, Y.Sano, I.Kanazawa, A.Tsujio, T. & Kaneko, Z. (1967) Metabolic effects of methionine in schizophrenic patients pretreated with a monoamine oxidase inhibitor. Nature 216, 1110–1111CrossRefGoogle ScholarPubMed
Kraepelin, E. (1921) Manic Depressive Insanity and Paranoia. E. & S. Livingstone Edinburgh, pp. 73; 97–98Google Scholar
Kufferle, B. & Grunberger, J. (1982) Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. In: Typical and Atypical Antidepressants. Clinical Practice (E. Costa and, G. Racagni, eds.), Raven Press, New York, pp. 175-180Google ScholarPubMed
Lipinski, J.F.Cohen, B.M.Altesman, R.A.Jones, B.Frankenburg, F.Tohen, M. & Waternaux, C. (1984) Open trial of S-adenosylmethionine for treatment of depression. Am. J. Psychiatry 141, 448–450Google ScholarPubMed
Mantero, M.Pastorin, R.Carolei, A. & Agnoli, A. (1975) Studio centroloata in doppio cieco (SAMe-imipramina) nelle sindromi depressive. Minerva Med. 66, 4098–4101Google Scholar
Matveichuk, T.S. (1969) The impact of a combined methionine and psychotropic treatment in patients with chronic schizophrenia. Zh. Neuropatol. Psikhiatr. 69, 1868–1871Google Scholar
Miccoli, L.Porro, V. & Bertolino, A. (1978) Comparison between the antidepressant activity of S-adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol. 33, 243–255Google ScholarPubMed
Monaco, P. & Quattrochi, F. (1979) Studio degli effetti antidepressive di un transmelitante biologico. Rivisti Di Neurologica 49, 417–439Google Scholar
Muscettola, G.Galzenati, M. & Balbi, A. (1982) SAMe versus placebo : a double-blind comparison in major depressive disorders.In: Typical and Atypical Antidepressants: Clinical Practice (E., Costa and G., Racagni, eds.), Raven Press: New York, pp. 151–156Google Scholar
Osmond, H. & Smythies, J. (1952) Schizophrenia: a new approach. J. Ment. Sci. 98, 309–315CrossRefGoogle ScholarPubMed
Park, L.C.Baldessarini, R.S. & Kety, S.S. (1965) Methionine effects on chronic schizophrenics. Arch. Gen. Psychiatry 12, 346–351CrossRefGoogle ScholarPubMed
Pollin, W.Cardon, P.V. & Kety, S.S. (1961) Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 133, 104–105CrossRefGoogle ScholarPubMed
Pope, H.G. & Lipinski, J.R. (1978) Diagnosis in schizophrenia and manic-depressive illness. Arch. Gen. Psychiatry 35, 811–828CrossRefGoogle ScholarPubMed
Smythies, J.R. & Antun, F. (1970) The biochemistry of psychosis. Scot. Med. J. 15, 34–40CrossRefGoogle Scholar
Spaide, J.Nevelor, L.Tolentino, J. & Himwich, H.E. (1969) Methionine and tryptophan loading in schizophrenic patients receiving a MAO inhibitor : correlation of behavioral and biochemical changes. Biol. Psychiatry 1, 227–233Google ScholarPubMed
Swazey, J.P. (1974) Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation. MIT Press, Cambridge, MS, pp. 283–286Google Scholar
Toone, B.Bottiglieri, T.Carney, M. & Reynolds, E.H. (1986) Pharmacology and therapeutic action of Sadenosyl- L-methionine (SAMe), putative antidepressant. Colt. Int. Neuro-Psychopharmacol. (abstr.) pp. 170–182Google Scholar
Submit a response

Comments

No Comments have been published for this article.